Dr Keyi Jiang, MD | |
228 Billerica Rd, Harvard Vanguard Medical Associates, Chelmsford, MA 01824-3604 | |
(978) 250-6300 | |
Not Available |
Full Name | Dr Keyi Jiang |
---|---|
Gender | Female |
Speciality | Pediatrics |
Location | 228 Billerica Rd, Chelmsford, Massachusetts |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1841500527 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208000000X | Pediatrics | C141768 (California) | Primary |
Entity Name | Southern California Permanente Medical Group |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1770515280 PECOS PAC ID: 6002729175 Enrollment ID: O20031110000678 |
News Archive
Medical Action Industries Inc. announced the acquisition of AVID Medical, Inc., a leading provider of custom procedure trays serving the healthcare industry. AVID's product line of custom procedure trays is complementary to Medical Action's leading position in single use medical products. Medical Action expects that the acquisition will increase its ability to serve healthcare providers in acute care facilities and surgery centers.
Patients with acute coronary syndrome undergoing angioplasty who received the anticoagulant drug bivalirudin did not show significant improvements in either of two co-primary endpoints-a composite of rate of death, heart attack or stroke at 30 days, or a composite of those events plus major bleeding-as compared to patients receiving standard anticoagulation therapy, according to a study presented at the American College of Cardiology's 64th Annual Scientific Session.
Sosei Group Corporation, a biopharmaceutical company, today announces the assignment of the drug discovery programme, SD281 and its analogues, to Biocopea Limited, a UK biotechnology company and subsidiary of PepTcell Limited. These compounds, based on a metabolite of a well-known drug, were shown by Sosei to have pronounced anti-inflammatory properties.
Dynavax Technologies Corporation today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold for the HEPLISAVTM Investigational New Drug (IND) application in individuals with chronic kidney disease.
› Verified 7 days ago
Mailing Address | Practice Location Address |
---|---|
Dr Keyi Jiang, MD 5601 De Soto Ave, Kaiser Permanente Woodland Hills Medical Center, Woodland Hills, CA 91367-6701 Ph: (818) 719-2115 | Dr Keyi Jiang, MD 228 Billerica Rd, Harvard Vanguard Medical Associates, Chelmsford, MA 01824-3604 Ph: (978) 250-6300 |
News Archive
Medical Action Industries Inc. announced the acquisition of AVID Medical, Inc., a leading provider of custom procedure trays serving the healthcare industry. AVID's product line of custom procedure trays is complementary to Medical Action's leading position in single use medical products. Medical Action expects that the acquisition will increase its ability to serve healthcare providers in acute care facilities and surgery centers.
Patients with acute coronary syndrome undergoing angioplasty who received the anticoagulant drug bivalirudin did not show significant improvements in either of two co-primary endpoints-a composite of rate of death, heart attack or stroke at 30 days, or a composite of those events plus major bleeding-as compared to patients receiving standard anticoagulation therapy, according to a study presented at the American College of Cardiology's 64th Annual Scientific Session.
Sosei Group Corporation, a biopharmaceutical company, today announces the assignment of the drug discovery programme, SD281 and its analogues, to Biocopea Limited, a UK biotechnology company and subsidiary of PepTcell Limited. These compounds, based on a metabolite of a well-known drug, were shown by Sosei to have pronounced anti-inflammatory properties.
Dynavax Technologies Corporation today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold for the HEPLISAVTM Investigational New Drug (IND) application in individuals with chronic kidney disease.
› Verified 7 days ago
Chandra Ramanathan, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 228 Billerica Rd, Chelmsford, MA 01824 Phone: 978-250-6000 | |
Dr. Mark Gordon Gilchrist, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 4 Meeting House Rd, Chelmsford, MA 01824 Phone: 978-250-4081 Fax: 978-250-3956 | |
Sheila L Morehouse, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 7 Village Sq, Chelmsford, MA 01824 Phone: 978-256-4363 | |
Jennifer Marie Liano, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 228 Billerica Rd, Chelmsford, MA 01824 Phone: 978-250-6300 | |
Francheyska Silfa Mazara, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 3 Kirby Ln, Chelmsford, MA 01824 Phone: 617-650-1685 | |
Dr. Lorna Shaw Melo, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 228 Billerica Rd, Pediatrics Dept, Chelmsford, MA 01824 Phone: 978-250-6300 | |
Beril Bayrak, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 7 Village Sq, Chelmsford, MA 01824 Phone: 978-256-4363 Fax: 978-256-1565 |